Literatur
Sheppard JD, Wirta DL, McLaurin E, Boehmer BE, Ciolin JB, Meides A, Schlter Th, Ousler GW, Usner D, Krösser S (2021) A water-free 0.1 % cyclosporine A solution for treatment of dry eye disease: results of the randomized phase 2B/3 ESSENCE study. Cornea 2021(40):10
Tauber J, Wirta DL, Sall K, Majmudar PA, Willen D, Krösser S, for the SEECASE study group (2021) A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease. Cornea 2021(40):1132–1140
Wirta DL, Torkildsen GL, Moreira HR, Lonsdale JD, Ciolino JB, Jemntsch G, Beckert M, Ousler GW, Steven Ph, Krösser S (2019) A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease. Ophthalmology. https://doi.org/10.1016/j.ophtha.2019.01.024
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
G. Geerling gibt eine geringfügige Tätigkeit als Berater für Novaliq GmbH an.
Additional information
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Geerling, G. Fluorierte Alkane – Eine differenzierte Betrachtung und Indikationsstellung ist sinnvoll. Ophthalmologie 120, 675–676 (2023). https://doi.org/10.1007/s00347-023-01867-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00347-023-01867-9